No. As of September 2026, Amphastar Pharmaceuticals, Inc. (AMPH) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 55.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 21.0% / 30% · Interest income / Revenue 1.10% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 55.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 21.0% / 33% · Receivables / Mkt Cap (36m) 16.6% / 49% · Interest income / Revenue 1.10% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 55.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 21.0% / 33.33% · Receivables / Mkt Cap (24m) 16.6% / 33.33% · Interest income / Revenue 1.10% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 36.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 16.3% / 33.33% · Receivables / Avg Assets (4Q) 9.19% / 33.33% · Interest income / Revenue 1.10% / 5% | Fail |
| FTSE | Debt / Total Assets 35.8% / 33.33% · (Cash+ST Inv) / Total Assets 13.5% / 33.33% · (Cash+Recv) / Total Assets 24.1% / 33.33% · Interest income / Revenue 1.10% / 5% | Fail |
No. As of September 2026, Amphastar Pharmaceuticals, Inc. (AMPH) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Amphastar Pharmaceuticals, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 1.10% of each dividend: Amphastar Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.2B. The Maz Rating grades it against the other companies in its sector.
Amphastar Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.10, Amphastar Pharmaceuticals, Inc. trades at 12.9x trailing earnings, 1.7x sales and 1.5x book value, with an EV/EBITDA of 7.9. Over the last twelve months it generated about $750M of revenue and $96M of net income. It runs a gross margin of 46.8%, an operating margin of 18.7% and a net margin of 13.3%. It shows return on equity of 12.6%, return on invested capital of 6.9% and a free cash flow yield of 11.2%. On the balance sheet: a debt-to-equity ratio of 0.85 and a current ratio of 3.32. Over the past 52 weeks the share price ranged from $16.65 to $31.00, with a beta of 0.94.
Amphastar Pharmaceuticals, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 3 Buy, 8 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.